PUBLISHER: KBV Research | PRODUCT CODE: 1397605
PUBLISHER: KBV Research | PRODUCT CODE: 1397605
The Europe Diabetic Footwear Market would witness market growth of 7.8% CAGR during the forecast period (2023-2030). In the year 2020, the Europe market's volume surged to 32,705.5 thousand Units, showcasing a growth of 7.8% (2019-2022).
The application of diabetic footwear extends beyond merely providing a comfortable fit. It addresses the unique challenges faced by individuals with diabetes, aiming to prevent foot ulcers, infections, and amputations. Diabetic footwear is designed to distribute pressure evenly across the foot, reducing the risk of pressure points that can lead to ulcers. This is especially vital for individuals suffering from diabetic neuropathy, which is a pathological state distinguished by nerve impairment resulting in a loss of sensation in the feet. The footwear incorporates cushioning and arch support to enhance comfort and reduce the impact on the feet during daily activities. This is essential for individuals with diabetes, as compromised foot sensitivity can result in injuries without the wearer being immediately aware.
By minimizing pressure points, diabetic shoes reduce the risk of excessive force on specific areas of the foot, which could otherwise lead to ulcers. The insoles of diabetic footwear are often made from materials that provide extra cushioning and shock absorption. This is particularly important for individuals with diabetic neuropathy as it helps to protect the feet from the impact of walking and other daily activities, reducing the risk of trauma that could lead to ulcers.
In accordance with the data from the International Diabetes Federation (IDF), diabetes prevalence (9.2%) and the number of individuals with diabetes (61 million) are expected to increase by 13% in the European region by 2045, according to IDF projections. The region exhibits the highest incidence of type 1 diabetes annually, with 31,000 new cases and the greatest number of children and adolescents affected (295,000). Additionally, at USD 3,086, the region has the second-highest average cost per person with diabetes. Diabetes incurred 189.3 billion USD in expenditures in 2021, representing 19.6% of global expenditures. Therefore, rising cases of diabetes in many countries of Europe will boost the demand for diabetic footwear in the region.
The Germany market dominated the Europe Diabetic Footwear Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $835 Million by 2030. The UK market is exhibiting a CAGR of 6.8% during (2023 - 2030). Additionally, The France market would experience a CAGR of 8.6% during (2023 - 2030).
Based on End User, the market is segmented into Women and Men. Based on Type, the market is segmented into Shoes, Sandals and Slippers. Based on Distribution Channel, the market is segmented into Specialty Stores, Online Platform, Footwear Stores and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include New Balance Athletics, Inc., SKECHERS USA, Inc., Orthofeet, Inc. (Webster Equity Partners), DJO Global (Enovis Corporation), Drew Shoe Corporation, Wolverine World Wide, Inc., Podartis Srl, I-Runner (Healer Health LLC), Pilgrim Shoes and Aetrx Worldwide, Inc.
Market Segments covered in the Report:
By End User (Volume, Thousand Units, USD Billion/Million, 2019-2030)
By Type (Volume, Thousand Units, USD Billion/Million, 2019-2030)
By Distribution Channel (Volume, Thousand Units, USD Billion/Million, 2019-2030)
By Country (Volume, Thousand Units, USD Billion/Million, 2019-2030)
Companies Profiled
Unique Offerings from KBV Research